Company intelligence / Profile preview

OncoGlory Biotech

Ownership: Private
Development stage: Other

Overview

OncoGlory Biotech is a clinical-stage biopharmaceutical company headquartered in Suzhou, China, focused on developing innovative small molecule therapeutics for oncology. The company specializes in modulating the tumor microenvironment to overcome resistance to immunotherapy and improve patient outcomes in hard-to-treat cancers. Its lead clinical candidate, OG202, is a selective inhibitor of the TGF-β receptor 1 (ALK5) currently being evaluated in Phase 2 trials for solid tumors. OncoGlory's pipeline also includes OG101, a CSF-1R inhibitor, and several undisclosed preclinical programs targeting immune-oncology pathways. The company was founded by industry veterans with experience at major global pharmaceutical firms and is backed by leading venture capital investors.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on OncoGlory Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OncoGlory Biotech.